Results 41 to 50 of about 3,026 (154)

Development of Peptide Glucosyltransferase Inhibitors With Comprehensive Coverage Across Clostridioides difficile Toxin B Sub‐Types

Biotechnology and Bioengineering, Volume 123, Issue 2, Page 310-323, February 2026.
ABSTRACT Clostridioides difficile infection presents an escalating clinical challenge due to the proliferation of hypervirulent and antibiotic‐resistant strains. The primary symptoms of disease, namely colitis and diarrhea, are induced by the release of two toxins: TcdA and TcdB.
Carly M. Catella, Sudeep Sarma, Caroline M. Hinesley, Corey E. Febo, Keith A. Breau, Deniz Durmusoglu, Ethan Purnell, Scott T. Magness, Carol K. Hall, Stefano Menegatti, Nathan Crook   +10 more
wiley   +1 more source

Decreased warfarin effects in elder with recurrent Clostridium difficile infection during fidaxomicin therapy: a case report

Clinical Management Issues, 2015
Clostridium difficile infection is a disease with increasing incidence, particularly in high‑riskpatients such as the elderly, immunocompromised patients, etc. We report an unexpected decrease of International Normalized Ratio (INR) response to warfarin
Antonio Riccardo Buonuomo, Maria Alessandra Foggia, Emanuela Zappulo, Guglielmo Borgia, Ivan Gentile   +4 more
doaj   +1 more source

Comparison of fidaxomicin to oral vancomycin for the treatment of Clostridioides difficile infection in hospitalized patients

Antimicrobial Stewardship & Healthcare Epidemiology, 2022
Background: Clostridioides difficile infection (CDI) is a major source of morbidity and mortality. Even after recovery, recurrent CDI (rCDI) occurs frequently, and concomitant antibiotic use for treatment of a concurrent non–C.
A. Krishna Rao, Qianzi Zhao, Jay Krishnan, Justin Bell, Oryan Henig, Jolene Daniel, Kara Sawaya, Owen Albin, John Mills, Lindsay Petty, Kevin Gregg, Daniel Kaul, Anurag Malani, Jason Pogue, Keith Kaye   +14 more
doaj   +1 more source

Improving Clinical Outcomes of Encapsulated Faecal Microbiota Transplantation for Clostridioides difficile Infection Through Empirical Donor Selection and Optimised Dosing: A Quality Improvement Study

Alimentary Pharmacology &Therapeutics, Volume 63, Issue 2, Page 276-287, January 2026.
In a large‐scale, multiple‐site Danish faecal microbiota transplantation (FMT) system, the cure rates in patients with Clostridioides difficile infection treated with encapsulated FMT were improved following exclusion of three low‐performing donors and implementation of a two‐dose FMT regimen.
Sara Ellegaard Paaske, Simon Mark Dahl Baunwall, Tone Rubak, Nina Rågård, Jens Kelsen, Mette Mejlby Hansen, Anders Bergh Lødrup, Søren Lyhne, Emilie Glavind, Christa Marie Culmback Fernis, Stine Hald, Lise Tornvig Erikstrup, Lars Vinter‐Jensen, Simon Lal, Susan Mikkelsen, Christian Erikstrup, Jens Frederik Dahlerup, Christian Lodberg Hvas   +17 more
wiley   +1 more source

The Concise Guide to PHARMACOLOGY 2025/26: Transporters

British Journal of Pharmacology, Volume 182, Issue S1, Page S404-S496, December 2025.
The Concise Guide to Pharmacology 2025/26 marks the seventh edition in this series of biennial publications in the British Journal of Pharmacology. Presented in landscape format, the guide provides a comparative overview of the pharmacology of drug target families. The concise nature of the Concise Guide refers to the style of presentation, being clear,
Stephen P. H. Alexander, Alasdair J. Gibb, Eamonn Kelly, Alistair A. Mathie, Chloe J. Peach, Emma L. Veale, Jane F. Armstrong, Elena Faccenda, Simon D. Harding, Christopher Southan, Jamie A. Davies, Laura Amarosi, Catriona M. H. Anderson, Philip M. Beart, Stefan Broer, Paul A. Dawson, Gergely Gyimesi, Bruno Hagenbuch, James R. Hammond, Jules C. Hancox, Michal Hershfinkel, Ken‐ichi Inui, Yoshikatsu Kanai, Stephan Kemp, Edmund R. S. Kunji, Gavin Stewart, Sotiria Tavoulari, David T. Thwaites, Tiziano Verri   +28 more
wiley   +1 more source

Bezlotoxumab as Treatment for Recurrent/Chronic Clostridioides difficile Infection in Pediatric Stem Cell Transplant Recipients: A Multi‐Institutional Experience

Pediatric Blood &Cancer, Volume 72, Issue 10, October 2025.
ABSTRACT Clostridioides difficile infection (CDI) represents a significant health risk to pediatric stem cell transplant (SCT) patients. In these patients, recurrent CDI is common, requiring prolonged antibiotic usage and increased hospitalization. Bezlotoxumab, a monoclonal antibody that targets the toxin responsible for CDI, has demonstrated efficacy
Aaron E. Fan, Shaikha Alqahtani, Natalie Dailey Garnes, Priti Tewari, Demetrios Petropoulos, Sajad Khazal, Kris Mahadeo, Paige DePriest, Irtiza N. Sheikh   +8 more
wiley   +1 more source

Management of Clostridium difficile in a developing nation

Archives of Pharmacy Practice, 2016
Introduction: Clostridium difficile is the most important definable cause of healthcare acquired diarrhea. Recommended treatments for Clostridium difficile infection (CDI) are metronidazole, oral vancomycin and fidaxomicin (a new narrow spectrum ...
Azadeh Nasrollah, Shiva Hashemi, Parvin Talebloo, Mehdi Rajabi, Syed Azhar Syed Sulaiman, Usman Abubakar   +5 more
doaj   +1 more source

Identification of Potential RBPJ-Specific Inhibitors for Blocking Notch Signaling in Breast Cancer Using a Drug Repurposing Strategy

Pharmaceuticals, 2022
Notch signaling is a key parameter in regulating cell fate during tissue homeostasis, and an aberrant Notch pathway can result in mammary gland carcinoma and has been associated with poor breast cancer diagnosis. Although inhibiting Notch signaling would
Mengjie Rui, Min Cai, Yu Zhou, Wen Zhang, Lianglai Gao, Ke Mi, Wei Ji, Dan Wang, Chunlai Feng   +8 more
doaj   +1 more source

Hypersensitivity Reactions Associated With Fidaxomicin Use [PDF]

Clinical Infectious Diseases, 2013
We report hypersensitivity reactions associated with fidaxomicin, an antibacterial drug approved for the treatment of Clostridium difficile-associated diarrhea. These reactions are viewed as significant because of severity and unexpected because fidaxomicin is minimally absorbed.
Dmitri E, Iarikov, John, Alexander, Sumathi, Nambiar   +2 more
openaire   +2 more sources

Gastrointestinal Infection Before Immune Checkpoint Inhibition Hinders Treatment Efficacy and Increases the Risk of Colitis

Cancer Medicine, Volume 14, Issue 15, August 2025.
ABSTRACT Background Gastrointestinal (GI) infections, which often result in or stem from intestinal dysbiosis, can affect the efficacy of immune checkpoint inhibitors (ICIs) and increase the risk of adverse effects, such as colitis. In this study, we explored the impact of GI infections before initiation of ICI therapy on the incidence and severity of ...
Malek Shatila, Kian Abdul‐Baki, Andres Urias Rivera, Kei Takigawa, Irene Jeong‐Ah Lee, Andrew Sullivan, Tanvi Gupta, Linfeng Lu, Raakhi Menon, Ayesha Khan, Hamza Salim, Elliot Baerman, Carolina Colli Cruz, Cristina Natha, Varun Vemulapalli, Garrett Coleman, Krishnavathana Varatharajalu, Christopher Fan, Pablo Okhuysen, Anthony J. Olszanski, Yan Zhou, Hao Chi Zhang, Mehnaz Shafi, Yinghong Wang   +23 more
wiley   +1 more source